A carregar...
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression o...
Na minha lista:
| Publicado no: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4984328/ https://ncbi.nlm.nih.gov/pubmed/27582886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16650155 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|